Context Therapeutics is a clinical-stage biopharmaceutical company developing T cell engaging bispecific antibodies for solid tumors.
The company reported a basic and diluted net loss per common share (EPS) of $(0.38) for 2025. Revenue figures were not reported in the provided financial statements.
The total net loss for 2025 was $36.1 million.
Research and development expenses reached $31.9 million in 2025. Year-end cash and cash equivalents totaled $66.0 million. This available capital is expected to fund the company’s operations into mid-2027.